Browse by Topic

(1-001) Enhancing Revenue for Clinical Pharmacy Services in the Indian Health Service

(1-002) Formation of an Outpatient Ketamine Infusion Clinic at the Cheyenne Veteran's Affairs Health Care System

(1-003) Matchmaker Metrics: Streamlining PGY-1 Pharmacy Residency Selections for Optimal Outcomes

(1-004) Optimizing Inventory Management Strategies in Outpatient Pharmacy Operations: A Comprehensive Analysis

(2-053) Linking Chronic Diseases with Negative Social Determinants of Health: Barriers to Effective Medication Management

(2-182) Business Proposal: Integration of clinical pharmacy services into the outpatient hematology-oncology setting

(3-019) Comparison of Illicit Drugs of Abuse Usage Rates Among the Army Reserve and the Active Army in 2024

(3-326) Optimizing Biosimilar Policies for Enhanced Healthcare Based on Boston-Area Hospitals

(4-001) Alvimopan: Medication Use Management Cost Savings Initiative

(4-002) Administrative Practice/Management /Financial Management/Human Resources

(4-003) Acute Care Formulary Standardization and Compliance Across a Multi-State Healthcare System

(4-004) Optimizing Pharmacy Staff Workflow Across a National Healthcare System to Improve Efficiency

(5-050) Establishing the Foundation for an Inpatient Pharmacy Operations Dashboard

(5-246) The Impact of the Inflation Reduction Act on Prescription Drug Costs and Pharmaceutical Innovation

(5-253) Assessing the Cost Implications of Transitioning Tablet Splitting from Nursing to Pharmacy

(5-255) Pediatric Chemotherapy Guideline Optimization Initiative: A QI Project

(5-272) Cost-Benefit Analysis of a Pharmacy Formulary for a Non-Profit Community Health Center

(5-277) Pharmacists’ Perceptions Regarding Immunization Services, Preference for Reimbursement, and Implications for Provider Status in New York.

(6-049) Assessing the Impact of an Integrated Health System Initiative on Anesthetic Gas Use and Associated Effects on Greenhouse Gas Emission on Hospital Spending

(6-081) Review of the Transition from Iron Sucrose to Ferric Gluconate at a Community Hospital

(6-115) Gastrointestinal Infusion Tracking of Internal and External Patients

(6-116) Implementation of Just-In Time Education via Automated Instructions on the Production Label for Optimal Vial Selection to Minimize Preventable Drug Waste

(7-002) An evaluation of storage methods for light-sensitive injectable drugs in the compounding suite

(7-009) Evaluating Cost for Generalized Myasthenia Gravis Treatment

(7-116) Tooling Towards Safer Care: Optimizing Clinical Pharmacists' Interventions in High Fall Risk Geriatric Patients to Combat Polypharmacy

(7-144) Appointment Scheduling Operator Wait Times: A Cross-Sectional Comparison between Harris Health and Peer Institutions

(7-145) Assess impact of a system restricted medication override list on percent override

(7-146) Optimization of an Enterprise Inventory Management System at a Community-focused Academic Medical Center

(7-282) Optimizing Medication Management: Reducing Costs through Recovery of Missing Medication Doses at a Regional Academic Medical Center

(7-295) Optimization of automated dispensing machines to reduce waste at an inpatient behavioral medicine facility within an academic medical center

(7-330) Implementation of Strategies to Enhance Pharmacy Efficiency and Financial Sustainability at William S. Middleton Memorial Veterans Hospital: A Comprehensive Approach to Cost-Saving Metrics and Revenue

(8-001) Budget Impact of Subcutaneous Immunoglobulin, Intravenous Immunoglobulin and Efgartigimod Alfa in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in the United States

(8-002) Spaghetti Map Technician Delivery Workflow Process Improvement

(8-003) Outpatient Formulary Development for Infusion Centers Across a Multi-State Healthcare System

(9-193) Comparative Analysis of Patient Financial Assistance Programs Amongst Large Academic Medical Centers

(9-279) Identifying Opportunities to Utilize Artificial Intelligence to Improve Efficiency and Accuracy of Medication Reconciliation through Different Phases of Care

(9-306) Cutting Pharmacy Waste: Establishing a Process to Streamline Excess Medication Sharing

(9-431) Leveraging an Algorithmic Approach to Enhance Inventory Management and Minimize Costs within an Acute-Care Pharmacy setting

(9-485) Evaluation of remote clinical interventions within a healthcare system: a quality improvement project

(9-486) Optimization of Evidence-Based Order Sets to Reduce Duplicate Medication and Drug-Drug Interaction Alerts and Alleviate Alert Fatigue in Pharmacists

(10-148) Cost-Benefit Analysis of Using Premix versus Compounded Oxytocin, Dexmedetomidine, and Bupivacaine and Fentanyl Epidural Continuous IV Infusions

(10-149) Medication Use Evaluation of Rush University Medical Center’s Non-Formulary Medication Requests

(10-270) Impact of a Patient Assistance Card Program on 30-Day Hospital Readmission Rate

(10-472) Improving HCAHPS Survey Scores through Enhancing Medications Communications: Interprofessional Collaboration between Internal Medicine and Clinical Pharmacy

(11-025) Optimizing Medication Spend within Value-Based Care through the High-Value Pharmacy Enterprise

(12-058) Evaluating Clinical Pharmacist Satisfaction of Cross Coverage during Paid Time Off (PTO)

(12-127) Limiting batched work by redesigning medication stocking workflows and its effect on pharmacy technician staffing requirements

(12-410) 503A (Category 3) Compounding Pharmacy Drug Utilization

(12-412) Comparison of provider versus pharmacist driven product selection on compliance with Vaccine for Children (VFC) program

(12-428) Expansion of Pharmacy Services to Improve Patient Care Outcomes in a Rural, Community Hospital

(13-035) Benefits of Implementing an Enterprise-Wide Formulary Strategy in Outpatient Physician Clinics

(13-076) Developing Pharmacy Processes for a National Group Purchasing Organization in Non-Acute Settings

(13-108) Strength in Supply: Evaluating the Impact of Secured Days on Hand Gains

(13-122) Advancing Specialty Medication Management: A Refill Protocol Initiative

(13-130) Patterns of Pharmacy Enterprise Employee Experience and Retention in a Large, Not-For-Profit, National Health-System

(13-178) Pharmacy Workforce Shortages: Developing a Sterile Compounding Certificate Program for Pharmacists and Technicians

(13-190) Addressing the Pharmacy Technician Workforce Shortage through Health-System Employer Sponsored Certification Training Program

(13-255) Economic Cost Optimization Interchange of Nebulizers for Inhalers (ECO-INHALE)

(13-256) Medication Claim Denial Prevention

(13-264) Assessing Team Member Satisfaction and Productivity with a Clinical Documentation Platform within a Health-System Specialty Pharmacy

(13-293) Pharmacist Interventions to Reduce Medication Medical Necessity Denials

(13-296) Impact of Implementing the Vaccines for Children (VFC) Program at a Regional Medical Center

(13-397) Standardization of the Retail Ordering Process of Chemotherapy Medications for Outpatient Clinic Use

(1-006) An Evaluation of Continuous Glucose Monitoring System Management by PACT Pharmacists in the Primary Care Setting

(1-007) Analysis of Adverse Drug Reactions Associated with Intravenous Iron Infusion Formulations in the Veterans Health Administration

(1-008) The effect of a prescribing protocol to manage patients with type II diabetes who are referred to a pharmacist-run clinic at a tribal health system

(1-009) Assessing screening practices for metabolic dysfunction-associated steatotic liver disease (MASLD) in Type II Diabetes Mellitus (T2DM) at Federal Health Center (FHCC) primary care clinics.

(1-010) Assessment of veterans diagnosed with acute kidney injury while on empagliflozin

(1-011) Cardiovascular Risk Reduction Using Statins in Patients with Type 2 Diabetes Mellitus at a Rural Veterans Affairs Healthcare System

(1-013) Clinical Pharmacist Interventions in Veterans Enrolled in Veteran Affairs Caribbean Healthcare Systems (VACHS) MOVE! Weight Management Program Receiving Glucagon-Like Peptide-1 Receptor Antagonists (GLP1-RAs)

(1-014) Comparison of Indicated Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Outcomes in the Veteran Population

(1-015) Crow Service Unit Asthma Control in Tribal Communities Pilot Initiative: Implementing Single Maintenance and Reliever Therapy in American Indians/Alaskan Natives with Asthma

(1-016) De-escalation of Inhaled Corticosteroids and Optimization of Guideline Directed Medical Therapy (GDMT) in Patients with Chronic Obstructive Pulmonary Disease

(1-017) Deprescribing of Sulfonylureas in Older Adults with Well-Controlled Type 2 Diabetes at VA Salt Lake City Health Care System

(1-018) Deprescribing Sulfonylureas in Patients Over the Age of 65 within the Boise VA Medical Center

(1-019) Effect of a formulary change from budesonide/formoterol to fluticasone/salmeterol on chronic obstructive pulmonary disease control among Veterans at the Veterans Affairs Maryland Health Care System

(1-020) Effect of Provider Education on COPD Prescribing Trends within a Federal Health Care Center

(1-021) Effects of Pharmacist Led De-escalation of Inhaled Corticosteroid Use in Veterans with Chronic Obstructive Pulmonary Disease.

(1-022) Enhancing Patient-Reported Weight Documentation: Impact of Educational Interventions on Weight Management Providers at Minneapolis Veterans Affairs Health Care System (MVAHCS)

(1-023) Enhancing the Utilization of Sodium-Glucose Cotransporter-2 Inhibitors in Rural Diabetic Veterans with Chronic Kidney Disease at Veteran Affairs Community-Based Outpatient Clinics in Central Iowa

(1-024) Evaluate Patient Satisfaction Through the Implementation of a Clinical Pharmacist Practitioner-Led Neurology Clinic

(1-025) Evaluating Discordance Between Hemoglobin A1c and Glucose Management Indicator in Patients with Diabetes and Chronic Kidney Disease

(1-026) Evaluating the Effects of Suicidal Ideation Counseling for Patients Beginning Antidepressant Treatment

(1-027) Evaluating the Impact of a Pharmacist-Run Gout Clinic in a VA Community Based Outpatient Clinic

(1-028) Evaluating the Impact of Early Follow-up on A1C Reduction After Initial Diabetes Specialist Consultation

(1-029) Evaluating the Impact of Pharmacogenomics Testing on Patient Care Outcomes: A Review of Veterans in the Montana VA Health Care System (MTVAHCS)

(1-030) Evaluating the Impact of Sulfonylurea Deprescribing in Hypoglycemia

(1-031) Evaluation of a Clinical Pharmacist-Led Weight Loss Clinic in an Outpatient Veterans Affairs Population

(1-032) Evaluation of Ambulatory Alcohol Detoxification Standard Operating Procedure Implementation

(1-033) Evaluation of blood pressure medication requirements after semaglutide initiation for weight loss

(1-034) Evaluation of interventions from pharmacist-led chronic kidney disease (CKD) focused clinic

(1-035) Evaluation of Interventions Made Following Hypoglycemia in a Veteran Population

(1-036) Evaluation of Patient Aligned Care Team Clinical Pharmacist Practitioner Interventions on Gout Management

(1-037) Evaluation of Pharmacist-Driven Statin Prescribing and Adherence Monitoring in Female Veterans

(1-038) Evaluation of prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic (GIP)/GLP-1 RAs in Veterans with type II diabetes and fatty liver disease

(1-039) Evaluation of Semaglutide Prescribing Practices in Patients for Weight Loss at the Boise VA Medical Center (VAMC)

(1-040) Evaluation of the Current Endocrinology Community Care Process at a Single Veterans Health Care System

(1-041) Evaluation of the Impact of a Clinical Pharmacist on Primary Care Outcomes in a Behavioral Health Clinic

(1-042) Evaluation of the Outpatient Prescribing of Sodium Glucose Co-transporter 2 Inhibitors at a Veterans Affairs Medical Center

(1-043) Evaluation of Veterans Affairs Patient-Aligned Care Team Clinical Pharmacist Practitioner Interventions in Chronic Obstructive Pulmonary Disease

(1-044) Evaluation of weight loss effects of semaglutide and patient adherence with the Weight Management Program for Veterans

(1-045) Identifying Patients at High Risk for Peripheral Artery Disease using Ankle-Brachial Index in Pharmacist-Led Screening Clinic

(1-046) Impact of a Patient-Aligned Care Team (PACT) Clinical Pharmacist Practitioner (CPP) on Patient Outcomes at the VA Maine Healthcare System

(1-047) Impact of a Shared Medical Appointment (SMA) for Cardiovascular Health Outcomes Within the Veterans Health Administration

(1-048) Impact of Clinical Pharmacists Intervention on COPD Outcomes

(1-049) Impact of Continuous Glucose Monitoring Systems on Glycemic Control in Patients with Type 2 Diabetes Mellitus

(1-050) Impact of Continuous Glucose Monitors on De-escalation of Diabetic Therapy in a Veteran Population

(1-051) Impact of Pharmacist Education on Continuous Glucose Monitor Prescribing in a Veteran Population

(1-052) Impact of Pharmacist Interventions on Chronic Obstructive Pulmonary Disease Exacerbations Among Patients at a Rural Veterans Affairs Hospital

(1-053) Impact of Pharmacist-Led Care on Diabetes Management Outcomes

(1-054) Impact of Real-Time Continuous Glucose Monitoring (rtCGM) on Glycemic Control and Hypoglycemia in Various Subpopulations

(1-055) Impact of semaglutide intervention in a pharmacist-managed dyslipidemia clinic

(1-056) Implementation of a Pain Order Menu and the Effects on Pain Management Prescribing within a VA Health System

(1-057) Implementation of a Pharmacist-Led Weight Loss Clinic at an Indian Health Service Facility

(1-058) Implementing a Healthy Heart Shared Medical Appointment (SMA) to Improve Lipid Outcomes and Increase Utilization of Statin Therapy in the Veteran Population

(1-059) Implementing Continuous Glucose Monitor Group Education Classes for Veterans led by Clinical Pharmacist Practitioners at the Veterans Affairs Central Ohio Healthcare System

(1-060) Improving Anatomy-Specific Screening for Transgender and Gender Diverse Veterans at the Minneapolis VA Health Care System (MVAHCS)

(1-061) Improving SGLT2 Inhibitor Utilization in Chronic Kidney Disease Patients with or without Diabetes: A Quality Improvement Initiative

(1-062) Initiation of a Comprehensive Medication Management Clinic for Patients with Complex Medication Regimens, Polypharmacy, or Recent Transition of Care

(1-063) Long-term Glycemic Control with the Use of Continuous Glucose Monitors in Veterans with Type 2 Diabetes

(1-064) Optimizing A1c Outcomes in Veterans: Evaluating Compliance to Dexcom G7 CGMs and Data Sharing Methods at a Veterans Affairs Medical Center (VAMC)

(1-065) Optimizing Outpatient Heart Failure Management through Sodium Glucose Co Transporter 2 (SGLT2) Inhibitor Initiation using the Federal Electronic Health Record (EHR) Dashboard

(1-066) Outcomes of Pharmacist-Led Weight Loss Management in Patients Using Semaglutide (Wegovy)

(1-067) Pharmacist-Led Deprescribing of Inappropriately Prescribed Inhaled Corticosteroids in Veterans with Chronic Obstructive Pulmonary Disease

(1-068) Pharmacist-Led Optimization of Sodium-Glucose Cotransporter-2 inhibitors in Veterans with Chronic Kidney Disease and Type 2 Diabetes Mellitus at the Carl Vinson VA Medical Center

(1-069) Pharmacogenomics-Guided Strategies to Improve Statin Therapy Acceptance and Initiation

(1-070) Pharmacy-based Interventions for Diabetic Patients on Canagliflozin with Impaired Renal Function

(1-071) Real-World incidence of pancreatitis when prescribed Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in a Veteran population

(1-072) Real-world Incidence of Thyroid Cancer when Prescribed Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in a Veteran Population

(1-074) Reducing the Risk of Hypoglycemic Events through Targeted Interventions Focused on Veterans at High Risk

(1-075) Retrospective Analysis of the Impact of Pharmacist Phone Appointments versus Face-to-Face Appointments on Veterans Reaching Glycemic Goals

(1-076) Semaglutide clinical outcomes in Native American patients at the Albuquerque Indian Health Center: A retrospective observational study

(1-077) Standardization of Protocols for Outpatient Management of Acute Hypoglycemia in a Veterans Affairs Medical Center

(1-078) Strategies for Maintaining Incretin Mimetic Therapy for Weight Management During Drug Shortages at a VA Medical Center

(1-079) Suicide-Related Events when using Glucagon Like Peptide 1 Receptor Agonists in a Veteran Population with a History of Mental Health Conditions

(1-080) The Effect of PACT CPP Targeted Population Health Management in Improving Health Equity for Statin Use in Women Veterans with ASCVD.

(1-081) The effects of clinical pharmacist management of type two diabetes using continuous glucose monitors on A1c at the Boise VA Medical Center

(1-082) The Impact of Clinical Pharmacist Collaboration with Primary Care Teams at a Community Based Outpatient Clinic (CBOC)

(1-083) Tolerability and Effects of Discontinuation of Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and Glucagon-like peptide-1 / Gastric inhibitory polypeptide receptor agonist (GLP-1/GIP RA)

(1-084) Utilizing the Primary Care Equity Dashboard to Target Statin Prescribing in Female Veterans with Diabetes.

(1-085) VA Puget Sound HTN Pathway Equity Analysis

(1-086) Veteran Outcomes after Implementing Methods to Optimize Continuous Glucose Monitoring (CGM) Prescribing and Education

(2-001) Short-term continuous glucose monitoring and its impact on pharmacist-led diabetes medication management and blood glucose levels

(2-029) Assessing the Outcomes of the Implementation of Lipid Screenings During Pharmacist-Led Medicare Annual Wellness Visits (MAWVs) for Statin Treated Patients

(2-033) Evaluating the usage and titration of glucagon-like peptide-1 receptor agonists in patients with uncontrolled type 2 diabetes mellitus

(2-062) Evaluating Diabetic Patient Adherence Amidst the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Shortage

(2-083) Exploring the Effects of Mounjaro®, a Dual GLP and GLP-1 Receptor Agonist, on Lipoprotein (a) Levels in Patients with Type 2 Diabetes

(2-085) Spanish Diabetes Group Education Sessions in a Medically Underserved Community

(2-087) Comparison of Basal Insulins in Type 2 Diabetes Mellitus with Concomitant Severe Chronic Kidney Disease or End Stage Renal Disease

(2-155) Approval Rates for Prior Authorizations of Commonly Prescribed Medications in a Patient-Centered Medical Home

(2-156) The Impact of Physician’s Experience and Pharmacist’s Communication Method on Accepting Recommendations for Potentially Inappropriate Medications in a Patient-Centered Medical Home

(2-157) Time Spent on Prior Authorizations for Commonly Prescribed Medications in a Patient-Centered Medical Home

(2-158) Rates of Potentially Inappropriate Medication Prescribing for Resident and Attending Physicians in a Patient-Centered Medical Home.

(2-189) Risk of Charley Horse Pain with Insulin Titration in Patients with Type 2 Diabetes Mellitus

(2-211) Impact on Health Outcomes and Medication Adherence of Patients Who Access Their Healthcare Portal in an Uninsured Population

(2-226) HIV Co-infection with Mycobacterium Szulgiae: Clinical Insights and Management Challenges

(2-277) Off-Label Use of Teplizumab in a Patient with Early Stage 3 Type 1 Diabetes Mellitus

(2-294) Drug-Drug Interactions During Statin Associated Immune-Mediated Necrotizing Myopathy Treatment with Pharmacogenomic Implications

(2-295) Enhancing Compliance to CDC Opioid Guidelines in an Anesthesiology Pain Clinic

(2-296) Improvement of Allodynia following Discontinuation of Semaglutide in a Patient with Type 2 Diabetes Mellitus and History of COVID-19

(2-338) Evaluation of Amiodarone Prescribing Trends

(2-339) Increasing Utilization of Statins in Type 2 Diabetes Patients

(2-353) Evaluating Patient Perceptions of Skin Disease during Pharmacist Interventions in Atopic Dermatitis

(2-354) Impact of Pharmacy Intern Interventions on Managing Hyperlipidemia in Patients with an LDL greater than 190 mg/dL

(2-383) Type 1 Diabetes Management Success with Tirzepatide, Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Use: A Case Report

(2-387) Optimizing Statin Education: Impact of Counseling Formats on Patient Understanding and Retention Phase 2 – Development of Visual and Auditory Educational Material

(2-394) Optimizing Statin Education: Impact of Counseling Formats on Patient Understanding and Retention: Phase 3- Evaluation of Educational Materials

(2-414) Evaluating Pharmacists' Confidence and Perceptions in Ambulatory Care Pharmacy Services: A Comparison Between Low and High Prescription Volumes

(2-415) From Barriers to Breakthroughs: The Role of Pharmacy in Reducing Emergency Department Visits through Medication Assistance Programs

(3-005) Evaluation of Patient Eligibility for Continuous Glucose Monitor Utilization at the East Hawaii Health Primary Care Clinic

(3-009) Assessing Pharmacist Impact on Lipid-Lowering Medication Prescribing in Patients with Diabetes in a Rural Setting

(3-011) Evaluation of Renal-Protective Medication Use in Patients with Type 2 Diabetes and Chronic Kidney Disease in a Primary Care Clinic

(3-017) Comparison of Medicare Semaglutide and GLP-1 Receptor Agonists Prescribing Claims and Kidney Disease Deaths by State in 2022

(3-055) Impact of Pharmacist-Led Insulin Pump Service in Primary Care

(3-073) Improving Access to Long-Acting Antipsychotic Injectables within a Federally Qualified Health Center

(3-090) A Retrospective Study Comparing Pharmacist and Nurse Collaboration to Standard of Care Obesity and Overweight Treatment and Outcomes in Primary Care

(3-091) Effect of Vitalograph Aerosol Inhalation Monitor Implementation on a Multidisciplinary Chronic Obstructive Pulmonary Disease (COPD) Clinic

(3-103) Impact of a Pharmacist-Led Heart Failure (HF) Guideline Directed Medical Therapy Titration Clinic on HF Related Emergency Department Visits and Hospital Readmissions

(3-115) Retrospective Analysis of Titration of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Beta-Blockers in Patients Post Acute Myocardial Infarction

(3-134) PREVENT and ASCVD Risk Calculators: Estimating 10-Year and 30-Year Patient Risk and Impact on Treatment Recommendations

(3-153) Utilizing pharmacogenomic tests to optimize pain management therapy in patients with rheumatological conditions at the Ambulatory Clinics of the University of Puerto Rico.

(3-154) The Diabetes Distress Scale and the Effects on Management of Glycemic Control

(3-170) Subcutaneous semaglutide overdose: a case report and literature review

(3-194) Blood pressure control in patients with type 2 diabetes: a retrospective chart review of patients at a family medicine clinic in rural Kentucky

(3-219) Elevating Diabetes Education: Exploring Perceptions and Barriers of Patients to Diabetes Education in an Underserved Community

(3-227) Correlation Analysis Between Fall and Fracture Occurrence in the Elderly Diabetic Population and Comorbid Conditions: a Quantitative Study

(3-232) Idiopathic and metabolic triggers leading to recurrent acute pancreatitis in a 30-year- old woman

(3-233) Redefining Patient Care: The Importance of Pharmacist-Led Initiatives in Enhancing Patient Advocacy

(3-257) Evaluating the Economic Impact of Reducing HbA1c Levels in Patients with Diabetes

(3-273) Implementation of Evolocumab in a Patient with Type 2 Diabetes and Underlying Atherosclerotic Cardiovascular Disease

(3-274) Improving Glycemic Control in Older Adults with Type 2 Diabetes Using 4-Day Insulin Patch for Mealtime Insulin Evidenced by Continuous Glucose Monitoring: A Case Report

(3-275) Optimizing Type 2 Diabetes Management in an Ambulatory Care Setting: Efficacy of GLP-1 RA and Basal Insulin Combination

(3-276) Osteoporosis: Know Bones About It

(3-277) Pesticides: From The Farm To The Fork/What Are We Eating?

(3-278) Review of the association between cannabis use and development of type 2 diabetes mellitus

(3-279) Screening for Autoantibodies and Distinguishing Between Type 1 Diabetes and Type 2 Diabetes: The Role of the Pharmacist

(3-280) Semaglutide-Associated Depressive Symptoms: A Case report Highlighting Potential Mental Health Adverse Effects in a patient treated for Obesity

(3-281) Weight Management with Semaglutide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk

(3-298) Case Report: Diabetic Patient with Sickle Cell Anemia

(3-299) Impact of Glucagon-Like Peptide-1 Receptor Agonists on Weight Changes in Antipsychotic-Treated Patients with Type 2 Diabetes Mellitus

(3-300) Managing Hypoglycemia in a Patient with Elevated A1C and Hypoglycemia Unawareness Using a Continuous Glucose Monitoring System: A Case Report

(3-307) Impact of Semaglutide on Alcohol Consumption : A Case Report of Dual Benefits in Weight Loss and Alcohol Reduction

(3-317) Incorporating Pharmacogenomic Data into Pain Management of Ehlers-Danlos Syndrome

(3-318) Use of Anti-Inflammatory Reliever Therapy Versus Albuterol Alone for Managing Exercise-Induced Bronchospasm

(3-327) Assessing remote blood pressure monitoring for the improvement of health care quality in a community-based organization

(3-328) Investigating Weight Loss Effects of GLP1 RAs and GLP1/GIP RAs at Boston Medical Center’s Endocrine Clinic Utilizing Clinical Pharmacy Follow-up

(4-005) Trend of SGLT2i Prescription Before and After Prior Authorization Removal

(4-006) Impact of a Family Medicine Residency Clinic Interdisciplinary Team on the Heart Failure Readmission Rates of Patients Diagnosed with Reduced Ejection Fraction Heart Failure (HFrEF)

(4-007) Efficacy and Tolerability of Subcutaneous Semaglutide and Tirzepatide Three Months Post-Initiation at a Pharmacist-Led Weight Loss Clinic

(4-008) Impact of Pharmacist Interventions in Deprescribing Inappropriate Statin Therapy

(4-009) Comparing Continuous and Traditional Glucose Monitoring on Diabetes Outcomes in a Pharmacist-Managed Clinic

(4-010) Development of Continuous Glucose Monitor (CGM) Electronic Medical Record (EMR) Tool for Ambulatory Glucose Profile (AGP) Data Tracking

(5-006) Chasing the Zebra! Unexplained Glycemic Stability after Insulin Discontinuation in Long-Standing Type 2 Diabetes Mellitus

(5-059) A Survey of Pharmacists Providing Ambulatory Care Pharmacy Services in Nebraska

(5-134) Evaluation of Clinical Outcomes in Uninsured Population with Diabetes at a Large Health System Utilizing a Free Medication Program

(5-194) Content analysis of patient-facing educational materials on medication use in dialysis

(5-195) Validation of the Medication Regimen Complexity Index in the Weight Management Ambulatory Care Setting

(5-212) Evaluation of a Shadowing Program on Student Confidence in Understanding the Role of an Ambulatory Care Clinical Pharmacist

(5-256) Achieving LDL-C Goals in Very High-Risk ASCVD Patients: A Retrospective Evaluation of Goal Attainment Across Lipid-Lowering Therapies

(5-267) Assessment of Adult Diabetes Management in Roatan, Honduras: A Multiyear Descriptive Study

(5-268) Maximizing Care and Savings in FQHCs: the Synergistic Union of Clinical Practice Pharmacists and the 340B Program

(5-278) Analysis of Student Knowledge and Perceptions of Ambulatory Care Pharmacy

(5-279) Evaluation of Proton Pump Inhibitor Prescribing Practices in a Primary Care Clinic

(5-280) The use of tobacco, e-cigarette or vaping among college students

(5-321) Impact of pharmacist-driven continuous glucose monitoring in ambulatory care pharmacy practice

(6-010) Evaluation of the Transition from GLP-RA to Tirzepatide in a Multi-Specialty Clinic

(6-022) Review of Health Outcomes Associated with Pharmacist Intervention in Ambulatory Care Management

(6-025) Evaluation of Tobacco/Nicotine Use Disorder Interventions Including Use of Guideline Directed Medications

(6-073) Stresses and Successes of Ambulatory Care Pharmacy: The Impact of Documentation

(6-076) Improving Inhaler Technique Utilizing the In-Check DIAL

(6-082) Evaluating the use and prescribing patterns of tirzepatide in an outpatient setting.

(6-180) Pharmacist-led patient interventions and their effects on decreasing inappropriate aspirin use in high bleed-risk individuals

(6-187) Retrospective, matched cohort study comparing LDL of patients on statin therapy with or without use of probiotics

(6-191) Critically Important, Never Urgent: Assessing Ambulatory Care in Osteoporosis Patients

(6-212) Patterns of Albuterol Use in Primary Care

(6-226) Comparing ASCVD Risk Assessment in Primary Care: PREVENT vs. Pooled-Cohort

(6-228) Ambulatory Care Pharmacists’ Impact on Smoking Cessation

(6-246) Evaluating weight loss among patients with type 2 diabetes mellitus (T2DM) newly treated with tirzepatide or switched from other glucagon-like 1 peptide receptor agonist (GLP1-RA).

(6-254) Conceptualizing health needs, beliefs and perceptions of palliative care of patients at a free clinic

(6-255) Evaluation of Self Monitoring of Blood Pressure Program at an Underserved Clinic

(6-279) Evaluation of Overbasalization in Veterans for the Treatment of Type 2 Diabetes Mellitus at Providence Veterans Medical Center (PVAMC)

(6-280) Identifying Opportunities for Pharmacist Intervention in the Treatment of Alcohol Use Disorder: A Retrospective Chart Review

(6-281) The Impact of Sleep and Psychological Co-morbidities on GLP-1 Agonist Efficacy in Ambulatory Adults

(6-340) 90-day Adherence to New Inpatient SGLT2 Inhibitor Starts Post Discharge

(7-007) Experiences with a Continuous Glucose Monitor While Learning Diabetes

(7-017) Effects of Remote Monitoring Platforms on Glycemic Control in Patients with Diabetes

(7-021) Effects of Patient Assistance Programs at Faith Family Medical Center

(7-074) Determining Atopic Dermatitis Treatment Response Through a Pharmacist-Driven Treat-to- Target Approach Using the Patient-Oriented Eczema Measure Questionnaire

(7-076) Evaluation of the utilization of the Multi Step Order Transitional workflow tool in the electronic health record within outpatient area of dermatology

(7-096) Evaluating the Success of a Pharmacist/Nurse Practitioner-Led Hypertension Clinic Referral System

(7-102) Evaluating Patient’s Perspectives from Interprofessional Diabetes Education Workshops at a Student-Run Free Clinic

(7-103) Metformin’s Dark Side: A Case Report on Nightmares Triggered by a Common Diabetes Drug

(7-117) Assessing Prescribing Patterns for Ezetimibe as Add-On Therapy to Statins for Secondary Prevention in a Federally Qualified Health Center

(7-147) Clinical Outcomes of Switching from U-100 Basal Insulin to Ultra-Long-Acting U-200 Insulin Degludec or U-300 Insulin Glargine

(7-148) Implementation of Continuous Glucose Monitoring (CGM) Services with Clinical Pharmacist Interventions in Patients Living with Diabetes and the Effect on Hemoglobin A1c

(7-237) Descriptive Report of Therapeutic Time in Range and Other Hypertension Metrics at a Charitable Health Clinic

(7-238) Satisfaction with Student Led National Diabetes Prevention Program in a Faith-Based Community

(7-273) Comparison of Hypertension Management Guidelines Utilizing the National Ambulatory Medical Care Survey (2019)

(7-274) Oral COVID-19 Therapy Utilization in an Outpatient Urban Facility

(7-284) Comparing the PREVENT and Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease Risk Assessment at a Diabetes Clinic in West Virginia

(7-316) Integration of Student Pharmacists into an Ambulatory Care Setting to Evaluate COPD Symptom Control and Inhaler Technique

(7-326) Examining the Impact of a Coordinated Care Transitions Program for Veterans with Chronic Obstructive Pulmonary Disease using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) Framework

(7-331) Implementation of Metabolic Report Cards to Enhance Quality Metrics within Patient Aligned Care Teams at the William S. Middleton Memorial Veterans Hospital

(7-332) It Takes a Village: Improved Prescribing of Sodium-Glucose Cotransporter-2 Inhibitors to Slow Chronic Kidney Disease Progression in High-Risk Veterans

(7-348) Evaluation of Vitamin B12 Monitoring in Patients Receiving Metformin Therapy in a Federally Qualified Health Center in Rural Wyoming

(7-349) Diagnosing the Overlooked: Latent Autoimmune Diabetes in Adults (LADA) in a Federally Qualified Health Center in Rural Wyoming- A Case Series

(7-350) Retrospective Assessment of the Relationship between Diabetes Distress and Pre-existing Depression and/or Anxiety Diagnoses

(7-351) Statin Eligibility vs. Prescription Reality: Analyzing Gaps in Type 2 Diabetes Care at a Family Medicine Residency Program

(8-004) Impact of Clinical Pharmacist-Led Non-Oncology Infusion Management in Tertiary Academic Medical Center Rheumatology Clinic

(8-005) Feasibility and Acceptability of Incorporating Telemedicine to Pharmacy Services in the Rheumatology Clinics of the School of Medicine of the University of Puerto Rico

(8-006) Implementation of Pharmacist-Driven Continuous Glucose Monitor (CGM) Education Service Within Primary Care

(8-007) A Comparison of Ambulatory Care Pharmacist Practice Models on Patient Access and Primary Care Provider (PCP) Workload Burden

(8-008) Impact of the Addition of Virtual Care in Ambulatory Care Clinical Pharmacy Diabetes Clinics on HgbA1c

(9-001) Evaluation of a Medication Synchronization Program as a Tool for Identifying Patients at Increased Risk for Type 2 Diabetes

(9-007) Impact of pharmacist facilitated Chronic Care Management calls compared to nurse facilitated Chronic Care Management calls on clinical markers in community dwelling adults

(9-038) Comparing Iron Deficiency Anemia Management Strategies Utilizing Oral Iron Supplementation between Healthcare Providers

(9-082) A Pharmacists Role in Enhancing Statin Therapy for Cardiovascular Disease Prevention and Treatment in Patients with Type 2 Diabetes in a Federally Qualified Health Center

(9-083) Impact of Pharmacist Involvement on Aspirin in Secondary Prevention at a Federally Qualified Health Center

(9-093) Change in Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Score after Pharmacist Intervention within Rural Federally Qualified Health Center (FQHC) Pulmonary Clinics

(9-094) Impact of Pharmacist-Led Hepatitis C Linkage to Care and Treatment Service on Cure Rates in a Federally Qualified Health Center

(9-097) Impact of a Pharmacist Diabetes Management Protocol Within a Telehealth Clinic at a Rural Health Center

(9-105) Impact of a Pharmacist-Led Lipid Management Service at a Hospital-Affiliated Heart and Vascular Clinic

(9-110) Evaluation of Treatment of COPD Patients Managed at University of Arkansas for Medical Sciences Capital Mall and Family Medical Center Outpatient Care Clinics

(9-121) GLP-1 Agonist Prescribing Trends in Medicare Patients with Type 2 Diabetes and Cardiovascular Disease

(9-173) Development and Impact of a Bariatric Surgery Clinical Pharmacist Program in an Outpatient Clinic Setting

(9-197) Impact of Diabetes Education Classes on Patient Retention and Outcomes

(9-245) Evaluating the Impact of Pharmacist Education and Implementation of a Meds-to-Beds Program Upon Hospital Discharge for Patients with Heart Failure

(9-260) Evaluating the impact of pharmacist interventions on HgbA1c within a diabetes management program: a retrospective study

(9-261) A Multi- Site Survey of Primary Care Providers’ Perceptions of Implementing Pharmacist Services in a Weight Loss Clinic

(9-270) Heartfelt Insights: Identifying Opportunities to Modify Cardiovascular Risk Factors in Inflammatory Arthritis Management

(9-271) Impact of Pharmacist Intervention on Increasing Adult HPV Vaccination Rate in an Outpatient Internal Medicine Clinic

(9-280) Assessment of custom task use within the electronic medical record to optimize a specialty pharmacy and ambulatory care integrated workflow

(9-293) Assessment of effective communication methods in the ambulatory care setting

(9-294) Evaluation of opportunities for communication standardization between ambulatory care pharmacy and health system-based community pharmacies

(9-295) Identification of electronic health-record enabled communication best practices to address patient concerns from ambulatory care pharmacy technicians to clinical pharmacists.

(9-323) Evaluating Pharmacists’ Impact on Fiscal Outcomes, Chronic Disease Management, and Care Quality through Analysis, Interpretation, and Reporting of Continuous Glucose Monitoring Data in Diabetes Management

(9-334) Evaluation of Clinical Pharmacist Intervention in a FQHC Setting Using Selected HEDIS Measures

(9-335) Pharmacist-Led Intervention to Increase Human Immunodeficiency Virus Pre-Exposure Prophylaxis Use in a Federally Qualified Health Center Setting

(9-337) Modifiable Causes of Heart Failure Readmissions at a Community Health Care System

(9-339) Medication Use Evaluation of Tirzepatide FDA Approved for Type 2 Diabetes in the Outpatient Setting

(9-340) Medication Use Evaluation on Apixaban in Patients with Venous Thromboembolism

(9-358) Implementation of a Pilot Pharmacist-Led Medication Therapy Management Clinic to Assess Feasibility and Acceptability

(9-363) Assessment of Heart Failure Guideline-Directed Medical Therapy Adherence and Barriers to Use in Cardiology and Primary Care Clinics

(9-376) Impact of Pharmacist-led Interventions on A1c Reduction using Continuous Glucose Monitoring in Uncontrolled Diabetes within a Federally Qualified Health Center Setting

(9-377) Impact of Pharmacist-Led Interventions on Patients Out of Range Blood Pressure at Federally Qualified Health Center

(9-406) The Role of Pharmacist Follow-Up Calls in Addressing Medication-Related Problems

(9-434) Impact of Pharmacist-Led Medication Review at Discharge on High-Risk Medicare Patients

(9-480) Optimizing Low-Density Lipoprotein Cholesterol Management in Atherosclerotic Cardiovascular Disease Patients: A Pharmacist-Physician Collaborative Protocol

(9-487) Evaluating the Impact of Pharmacist-Led Transitions of Care Interventions on 30-Day Hospital Readmissions

(10-014) Impact of clinical pharmacy team intervention on naloxone fills in patients on chronic opioid therapy

(10-015) Evaluating the Impact of “On the Spot” – a Remote Pharmacy Hypertension Consult Service

(10-025) Evaluation of the Impact of a Pharmacist-led Smoking Cessation Clinic Within a Primary Care Setting

(10-043) Evaluation of Clinical Outcomes After Expansion of Ambulatory Pharmacist Services to Augusta University Care Center (AUCC) Primary Care Clinics

(10-049) Inappropriate Use of Inhaled Corticosteroids (ICS) in Patients with Chronic Obstructive Pulmonary Disease (COPD)

(10-066) Analysis of Predictors for Treatment Outcomes for Patients Enrolled in a Medication for Opioid Use Disorder Program at a Community Health Center

(10-067) Evaluation of Antibiotic Prescribing for Acute Upper Respiratory Infections at a Community Health Center by an Expanded Antimicrobial Stewardship Team

(10-081) Telehealth vs In-Person Pharmacist Led Ambulatory Care Visits for Diabetes Control

(10-085) Outcomes of In-person versus Telehealth Encounters for Ambulatory Care Patients in Pharmacotherapy Clinics

(10-118) Use of Inhaled Corticosteroid and Formoterol Combination Inhalers as Asthma Reliever Medication at a Safety Net Health System

(10-134) Descriptive Analysis of Pharmacist Impact on New Anticoagulant Therapy Prior to Community Hospital Discharge

(10-146) Changes in Tobacco Usage in Patients Taking GLP-1 Receptor Agonists or GIP/GLP-1 Receptor Agonists

(10-150) Impact of Pharmacist on Continuous Glucose Monitoring Usage and Management of Patients with Type 2 Diabetes in the Primary Care Setting

(10-155) Impact of Pharmacist-led Medication Therapy Management (MTM) Visits on Medication Access, Adherence, and Clinical Outcomes for Patients Prescribed Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(10-178) Impact of Ambulatory Care Pharmacist Interventions on Patients Initiated on a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) in a Weight Management Clinic

(10-187) Impact of Pharmacist Management of Continuous Glucose Monitors on Diabetes Outcomes

(10-188) Piloting Chronic Care Management Billing Involving Pharmacist in Primary Care

(10-198) Comparative Analysis of Glycemic Control Using Different Continuous Glucose Monitoring (CGM) Devices

(10-199) Insulin Dose Change in Patients Starting and Titrating Injectable GLP-1 Receptor Agonists Under Pharmacist Management

(10-205) Evaluation of Insulin After Initiation of Once-Weekly Glucagon-Like Peptide-1 (GLP-1) or GLP-1/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Patients with Type-2 Diabetes Mellitus

(10-206) Implementation of a Pharmacist in the Management of Postpartum Hypertension in an Obstetrics and Gynecology Clinic

(10-207) Evaluation of the Effectiveness of Pharmacist Follow-Up in Primary Care Clinics for Urgent Care Patients with Hypertension

(10-212) Evaluating the Impact of Multidisciplinary Care on Opioid Use Disorder: A Retrospective Study of Buprenorphine/Naloxone-Assisted Treatment in a Family Medicine Residency

(10-233) Analysis of readmission rates for patients with diabetes managed in the outpatient setting by pharmacists versus physicians: a retrospective study

(10-236) Prescribers Adherence to Guideline-directed Medical Therapy in Patients with Albuminuric Chronic Kidney Disease and Type 2 Diabetes: a nephro-protective view

(10-278) Empowering Pharmacists to Enhance Patient Experience and Improve Medication Safety in Chronic Kidney Disease Patients

(10-307) Analysis of Clinical Outcomes in Patients Treated with Inclisiran

(10-317) Outcomes of a Transitions of Care Pharmacy Program Expansion

(10-338) Impact of Pharmacist-Led Hepatitis C Clinic on Hepatitis A and B Vaccination Rates and Treatment Outcomes

(10-348) Impact of an Ambulatory Care Pharmacist-Managed Diabetes Program in a Rural Outpatient Setting: Improving Glycemic Control with Continuous Glucose Monitoring Systems

(10-350) Analyzing the Impact and Safety of Sodium-Glucose Cotransporter-2 inhibitors in a Federally Qualified Health Center

(10-381) Optimizing Guideline Directed Medical Therapy on Discharge for Patients with Heart Failure with Reduced Ejection Fraction in a Community Hospital

(10-390) Impact of Clinical Decision Support Within the Electronic Medical Record on Benzodiazepine Prescribing

(10-391) Impact of Corresponding Responsibility on Opioid Dispensing

(10-393) Impact of Clinical Pharmacy Intervention on Dose Titration of Liraglutide in Patients With Type 2 Diabetes Mellitus

(10-418) Evaluating Confidence and Perceptions of Continuous Glucose Monitors among Healthcare Professionals Before and After a Sensor Wear Experience in a Primary Care Setting

(10-419) Evaluation of the efficacy and safety of weight loss medications in a community health center

(10-420) HbA1C Improvement in Type 2 Diabetes with Continuous Glucose Monitoring Compared to Standard Care

(10-436) Evaluating the Impact of Targeted Medication Review on Appropriate Aripiprazole Dosing to Mitigate Adverse Drug Reactions

(10-448) Impact of Continuous Glucose Monitoring and Clinical Pharmacy Services on Glycemic Control and Other Diabetes-Related Outcomes at a Federally Qualified Health Center

(10-449) Investigation of the Metabolic Consequences of Antipsychotic (AP) Therapy With and Without Weight Gain at a Federally Qualified Health Center (FQHC)

(10-453) Impact of an Anticoagulation Management Service-led Intervention on Rates of Antiplatelet and Gastric Bleeding Prophylaxis Use in Ambulatory Care Patients on Background Direct Oral Anticoagulants

(11-001) Evaluating the Appropriate Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease

(11-006) Navigating the GLP-1/GIP Shortage: Consequences for Insulin Management, Glycemic Control, and Adherence in Patients with Type 2 Diabetes

(11-016) The Impact of Pharmacist-driven Continuous Glucose Monitoring (CGM) Services in Urban Patients with Diabetes Mellitus

(11-033) Overbasalization Overload: Navigating Next Steps in Diabetes Care

(11-060) Evaluation of Antibiotic Utilization for Urinary Tract Infections (UTIs) in Rural Health Primary Care Clinics

(11-061) Utilization of Maintenance and Rescue Therapy (MART) for Asthma at an Internal Medicine Residency Clinic

(11-069) Evaluating missed opportunities for Sodium-glucose cotransporter-2 inhibitors initiation in the outpatient setting for patients with diabetes, heart failure, kidney disease, or any combination thereof

(11-077) Exploring Primary Care Clinicians' Knowledge of Psychotropic Pharmacogenomics and Identifying Patients More Likely to Benefit from Testing Pre- and Post-Training at a Rural-facing Healthcare System

(11-096) Evaluating Helicobacter Pylori Treatment Failures at CentraCare Family Health Clinic

(11-125) Geriatricians’ Perceptions of Cognitive Screening of Older Adults in the Community Pharmacy Setting

(11-129) Identifying the Barriers to Primary Medication Adherence in a Pediatric Cystic Fibrosis Clinic

(11-157) Evaluating the Difference of Time in Therapeutic Range for International Normalized Ratio Values Between Home Testers and in Clinic Warfarin Monitoring

(11-171) Relationship Between Diabetes Distress Scale-2 (DDS2) Results and Diabetes Management Parameters

(11-172) Charting the Course of Care: Assessing Hepatitis C Screening and Eradication Efforts at a Federally Qualified Health Center

(11-183) Implementation of Pulmonology Referrals to Ambulatory Primary Care Pharmacists for Comprehensive Management of Chronic Obstructive Pulmonary Disease in a Community, Teaching Health System

(11-188) Implementation of a clinical pharmacist’s role within an interdisciplinary heart failure clinic

(11-214) Implementation of a Pharmacist-driven Service for Prescribing Pre- and Post-Exposure Prophylaxis Medications for Human Immunodeficiency Virus Prevention in a Community Pharmacy Setting

(11-229) Hypertension Harmony: Assessing the Effectiveness of Provider-Pharmacist Hypertension Management in Primary Care and Cardiology Ambulatory Clinics

(11-273) Comparison of Type 2 Diabetes Mellitus Management by an Ambulatory Care Pharmacist vs. Usual Care in a Medically Underserved Population

(11-283) Impact of Ambulatory Care Pharmacists on Gap Closure for Pediatric Asthma Within a Health System

(11-298) PREVENT vs. ASCVD Risk Calculator; Utilization and Analysis of New Cardiovascular Risk Calculator from the American Heart Association

(11-305) Evaluating the impact of an ambulatory-care pharmacist-led medication refill management pilot program on primary care practices.

(11-318) Effect of Botulinum toxin or CGRP in reducing the amount of abortive treatment in patients with chronic migraines

(11-416) Evaluation of warfarin management in patients with subtherapeutic INR

(11-442) The Impact of Pharmacist Involvement within an HIV Clinic on Chronic Disease State Management

(12-002) Evaluation of Trends in Medical and Pharmacy Spend for Patients Treated with GLP-1 RAs and dual GIP/GLP-1 RAs

(12-028) Characterizing the Use and Access of Anticoagulants for Management of Deep Vein Thrombosis in a Pharmacist-Driven Clinic

(12-057) Assessment of Anti-Obesity Medications for Patients Discontinuing GLP-1 Receptor Agonists

(12-059) Comparison of Hepatitis C Virus Medication Management Between Clinical Pharmacist Practitioners and Other Provider Types in the Primary Care Setting

(12-067) Aspirin Use for Primary Versus Secondary Prevention Among Patients Older Than 75 Years

(12-068) Specialty Medication Lab Monitoring Pilot to Promote Compliance in Rheumatology and Neurology Clinic

(12-089) Risk of Lower Limb Amputations in Type 2 Diabetes Mellitus (T2DM) Patients with Diabetic Foot Infections and Using a Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor

(12-125) Impact of Pharmacist Intervention on Percentage of INRs in Range in Patients Who Are Being Managed for Anticoagulation Therapy with Warfarin

(12-126) Impact of Pharmacist Transitions of Care Interventions on Hospital Readmission Rates in Heart Failure Patients

(12-146) Optimizing Transitions of Care: The Impact of Pharmacist-Led Interventions on Readmission Rates and Patient Outcomes

(12-149) Retrospective Review of Type 2 Diabetes Control in Patients Using Continuous Glucose Monitoring on Hemoglobin A1C in a Pharmacist Led Outpatient Medication Management Clinic

(12-152) Assessing Blood Pressure Targets: Evaluation of Optimal Blood Pressure Lowering

(12-159) Comparing the Efficacy of Glucagon-Like Peptide (GLP1) Agonists on Weight Loss compared to Control Group in Heart Failure Patients with Preserved Ejection Fraction

(12-167) Developing a pharmacist-led Medicaid annual wellness pilot program

(12-195) A Superior Therapy: The Clinical Pharmacist's Role in Warfarin to DOAC Transitions

(12-196) Improving Chronic Kidney Disease (CKD) Management in Primary Care with support from the Systems of Excellence

(12-197) Rates of Outpatient Guideline Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction

(12-227) Optimization of a Pharmacist Led Asthma Management Program for Patients with Uncontrolled Asthma

(12-230) Impact of home blood pressure monitors on blood pressure control within a managed care delivery system

(12-257) Pharmacist Managed Blood Pressure Control in a Rural Ambulatory Care Setting: A Retrospective Disease State Evaluation

(12-258) Impact of Collaborative Pharmacist-Led Diabetes Management in Rural Areas on A1C Levels

(12-262) Assessing Adherence of Hypertension Medications in Adult Patients at a Federally Qualified Health Center (FQHC)

(12-263) Evaluating the impact of clinical pharmacy services on rates of ED visits and hospitalizations among complex patients at an FQHC

(12-280) Assessing the appropriateness of antibiotic prescribing for acute sinusitis in adult patients seen at a rural Family Medicine Center

(12-287) Evaluation of The Prescribing Patterns of ICS- formoterol in Asthma Patients

(12-290) Switching Patterns of Biologics or Small Molecule Agents for Psoriasis in Geisinger Outpatient Dermatology Clinics

(12-307) Enhancing Timely Access to Medication Changes: The Role of Ambulatory Care Pharmacists in Overcoming Transitions of Care Challenges

(12-331) Achievement of LDL-C goal in patients with clinical atherosclerotic cardiovascular disease

(12-332) Medication Use Evaluation of Glucagon Prescribing in Patients Taking Insulin with a History of Hypoglycemia

(12-339) Evaluation of Opioid Selection for Chronic Lower Back Pain

(12-345) Evaluation of Patients Transitioned from Single to Multiple Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease and Asthma

(12-387) Impact of pharmacist interventions in the management of diabetes in a primary care setting in Puerto Rico

(12-409) Use of Glucagon-like Peptide-1 Receptor Agonists and Dual Gastric Inhibitory Polypeptide/Glucagon-like Peptide-1 Receptor Agonists to Achieve Successful Weight Loss Post Bariatric Surgery

(12-413) Impact of Ambulatory Care Pharmacy Interns on Pharmacists’ Workflow in the Primary Care Setting

(12-437) Evaluating Appropriate Use of Contraceptive Pharmacotherapy at a Family Medicine Clinic in a Federally Qualified Health Center

(12-449) Adherence to Antidepressants in a Federally Qualified Health Center

(13-001) Multidisciplinary approach to caring for women with gestational diabetes: Impact of clinical pharmacy visits on glycemic control and perinatal outcomes

(13-012) Impact of Pharmacist Driven Diabetes Self-Management Education and Support

(13-030) Process Development and Financial Sustainability of CGM Utilization in a Family Medicine Resident Clinic

(13-078) Clinical Impact of GLP-1 and GIP/GLP-1 Receptor Agonist Access Issues in a Primary Care Setting

(13-087) Evaluation of Pharmacists’ Impact on Diabetes Care with Continuous Glucose Monitoring (CGM) Technology in the Outpatient Setting

(13-088) Pillars of Care: Impact of a Heart Failure Pharmacist on Optimization of Guideline Directed Medical Therapy

(13-117) Evaluating the effectiveness of an interdisciplinary clinic: A one-stop shop for high-risk Medicare patients

(13-154) Assessing Clinical Pharmacy Interventions Impact on Adherence to Medication-Assisted Treatment

(13-155) Impact of Clinical Pharmacy Team on Closing the Care Gap for Eligible Patients With an ASCVD Diagnosis Not Receiving Aspirin

(13-175) Assessing the Effect of a Pharmacist-Led Refill Clinic Intervention on Medication Adherence in Patients with Diabetes

(13-194) Efficacy of SGLT2 inhibitor and GLP1 receptor agonist combination therapy in patients with type 2 diabetes in a county hospital health system

(13-195) Evaluation of Attaining Goal A1c by Pharmacist-Lead Interventions at a 340B Institution

(13-237) Glucagon-Like Peptide-1 Receptor Agonist Prescribing Rates and Determinants of Use in a Predominantly Hispanic Population at a County Hospital Health System in South Texas

(13-246) Pharmacist Medication Reconciliation and Provider Efficiency of Medication Review in a Geriatric Population

(13-247) Utilization of an ambulatory care pharmacist to improve hospital readmission rates in a senior health clinic

(13-283) How Does the Implementation of a Palliative Care Pharmacist Role Impact Patient Outcomes and Care Quality in a Home-Based Clinic?

(13-294) Elevating Quality of Care: SmartSet Implementation for Workflow Optimization

(13-304) Establishing a Pharmacist Workflow to Improve Transition from Community Hospital to Skilled Nursing Facility Care

(13-320) Impact of Pharmacist-Recommended Guideline-Directed Medication Therapy Optimization on 30-Day Hospital Readmissions in High-Risk Heart Failure Patients

(13-329) Evaluation of Ambulatory Care Pharmacist Interventions on Medication Adherence Metrics

(13-338) Assessing the Impact of Incorporating Insulin Pump Therapy in Pharmacist Led Diabetes Management in an Ambulatory Care Setting

(13-339) Implementing a Pathway for Emergency Department Providers to Refer Patients with Uncontrolled Type Two Diabetes Mellitus to a Pharmacist-Led Ambulatory Care Clinic

(13-349) Evaluation of Clinical Pharmacist Collaborative Management of Obesity in the Primary Care Clinic

(13-385) Evaluating Time to Access Opioid Treatment for Patients with Insurance That Requires a SEMP Prior Authorization Form versus Not at the Edwards Cancer Institute

(13-400) Optimizing the Integration of Pharmacist Providers in Ambulatory Care Clinics

(13-404) Development of Chronic Disease Management Training and Competency Plans for Pharmacists in the Ambulatory Care Setting

(13-416) Financial Impact of Ambulatory Care Pharmacists on Provider Retention

(13-417) Implementing a Population Health Approach to Direct Oral Anticoagulant (DOAC) Management – Phase II

(1-087) Anticoagulation Stewardship: Enhancing Upper Gastrointestinal Bleed Risk Management in Veterans on Concomitant Anticoagulant and Antiplatelet Therapy Through Risk Stratification and Workflow Optimization

(1-088) Aspirin versus Direct Oral Anticoagulants for Thromboprophylaxis after Total Knee and Hip Arthroplasty

(1-089) Assessing Heparin Infusion Initiation and Adjustment for Elevated Baseline Anti-Xa Levels in Hospitalized Veterans: A Quality Improvement Project in a VA Healthcare System

(1-090) Assessing the Effectiveness of the Miami Veterans Affairs Transitions of Care Program: Patient Follow-Up with Pharmacists for Anticoagulation Management After Hospital Discharge

(1-091) Characterization and Clinical Outcomes of Inappropriate Direct Oral Anticoagulant Dosing in Atrial Arrhythmia

(1-092) Comparison of Recurrent Venous Thromboembolism Rates in Patients With a History of Bariatric Surgery on Warfarin Compared to Rivaroxaban or Apixaban

(1-093) Effect of Prescribing Metoprolol Succinate Versus Carvedilol Therapy on Administration of Other Guideline Directed Therapy for Heart Failure with Reduced Ejection Fraction

(1-094) Evaluating the Impact of Implementation of Pharmacist Led Clinic on Antiarrhythmic Monitoring at a Rural Veterans Affairs Hospital

(1-095) Evaluating the Use of Sodium-Glucose Co-Transport 2 Inhibitors in Veterans with Heart Failure Preserved Ejection Fraction

(1-096) Evaluation of Anticoagulation Reversal Protocols at a Veterans Affairs Medical Center

(1-097) Evaluation of Dofetilide and Sotalol Protocol Deviations During Inpatient Hospitalization

(1-098) Evaluation of Guideline-Directed Medical Therapy in Heart Failure with Preserved Ejection Fraction at VA Greater Los Angeles Heart Failure Clinics

(1-099) Evaluation of Iron Deficiency Status in Patients Admitted with Acute Decompensated Heart Failure

(1-100) Evaluation of PCKS9 Inhibitor Adherence within a Veterans Affairs Cohort

(1-101) Evaluation of Semaglutide in Heart Failure patients with preserved Ejection Fraction with Type 2 Diabetes and/or Obesity Readmitted in 90 days post Heart Failure hospitalization

(1-102) Evaluation of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Initiation in Veterans Discharged Nationally After Acute Decompensated Heart Failure

(1-103) Evaluation of Treatments for Atrial Fibrillation Prior to Intensive Care Unit Admission

(1-104) Implementation of a Pharmacy-Managed Dofetilide Monitoring Program at VA Maine Healthcare System

(1-105) Integration of Pharmacist-Led Heart Failure Recommendations During Hospitalization

(1-106) Medication Use Evaluation (MUE) Project on Aspirin Utilization in Patients with Atrial Fibrillation on Apixaban

(1-107) Optimization of guideline-directed medical therapy (GDMT) in veterans with an acute heart failure reduced ejection fraction (HFrEF) exacerbation prior to hospital discharge

(1-108) Outpatient Initiation of Sotalol

(1-109) Pharmacist Interventions for Patients with Heart Failure via Home Telehealth

(1-110) Quality Improvement Evaluation of Periprocedural Anticoagulation Management at the Miami Veterans Affairs Healthcare System

(1-111) Stroke Prevention in Atrial Fibrillation/Flutter - Identifying Health Disparities in Anticoagulation Prescribing Practices - At VA Sierra Nevada Medical Center

(1-112) Safety and Efficacy of Direct Oral Anticoagulants in Veterans with Obesity

(2-005) Evaluation of Adverse Event Reporting of Sotagliflozin to the U.S. Food and Drug Administration

(2-006) Evaluation of Appropriate Oral Anticoagulation Use in Patients with Atrial Fibrillation

(2-051) Association of Perceived Risks of Health Behaviors with Problematic Substance Use: Raising Awareness of Health Education Opportunities

(2-130) The Impact of Glucuronolactone on Cardiovascular Parameters in Energy Drinks

(2-136) Exploring the Acute Hemodynamic Effects of Normatec 3 Therapy

(2-143) Tolerability Of Sodium Glucose Cotransporter 2 Inhibitors in Left Ventricular Assist Device Patients

(2-168) Analysis of a Systematic Program to Transition Patients on Warfarin to Direct Oral Anticoagulants

(2-172) Turmeric - Warfarin Interaction Resulting in Supratherapeutic INR, Bleeding, and Hospitalization

(2-227) Sotatercept: Breathing New Life into Pulmonary Arterial Hypertension Treatment

(2-228) Enhanced Anti-inflammatory Effects of Liraglutide when Combined with Roflumilast in Cardiac Cells

(2-229) Investigating Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors for Safe and Effective Use in Heart Failure with Reduced Ejection Fraction: A Systematic Review of the Literature

(2-230) Navigating the Dual Challenges of Pain Management in Patients with Pain Syndromes and Cardiovascular Disorders: A Scoping Review

(2-280) A Retrospective Chart Review of the Use of Guideline Directed Mediated Therapy in Patients with Heart Failure Referred for Pharmacy Consultation at a Community Hospital

(2-297) Evaluating the Efficacy of Enteral P2Y12 Inhibitors in Preventing Acute Stent Thrombosis Post-Percutaneous Coronary Intervention with Drug-Eluting Stents in ST-Elevation Myocardial Infarction with Cardiogenic Shock

(2-332) Evaluation of Nitroprusside Infusions in Cardiothoracic Surgery Patients in a Community Hospital

(2-340) Ambulatory Guideline-Directed Medical Therapy in Heart Failure with Preserved Ejection Fraction: Real-World Data from a Large Academic Center Cohort

(2-355) Evaluation of International Normalized Ratio Values in Patients Receiving Warfarin Therapy Using Vizient’s International Normalized Ratio-Based Metric Performance

(2-356) Octreotide to Prevent or Reduce Gastrointestinal Bleeding in Patients with Left Ventricular Assist Devices

(2-375) Exploring Brugada Syndrome and Its Role in Sudden Cardiac Death: Pharmacological Management Strategies

(2-395) Implementation of Cardiology Provider Report Cards to Improve Heart Failure Guideline-Directed Medical Therapy Prescribing

(2-416) Analysis of the Utilization of Intravenous (IV) Acetaminophen in the Perioperative Setting After Cardiothoracic Surgery

(3-020) Warfarin management in a rural physician-run clinic: Efficacy of In-Clinic Testing Compared to Home Monitoring

(3-022) Prevalence and Dosing of Direct Oral Anticoagulants in the Management of Left Ventricular Thrombus

(3-056) Aspirin Use for Secondary Cardiovascular Disease Prevention in Jamaica: Adherence and Barriers

(3-057) Evaluating Twice Daily versus Thrice Daily Low Dose Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Elderly Hospitalized Patients

(3-092) Dual Antiplatelet Therapy Compared to Therapeutic Anticoagulation Status-Post Left Atrial Appendage Occlusion

(3-093) Pharmacogenomic guided optimization of P2Y12 inhibitor therapy

(3-094) Utilization of Effective Diuresis in Patients Admitted for Acute Decompensated Heart Failure

(3-104) Exploring Characteristics of Patients Potentially Eligible for Transition from Warfarin to Direct Oral Anticoagulants: A Descriptive Study in an Anticoagulation Clinic

(3-107) Blood Factor Utilization Evaluation in Cardiovascular Surgery

(3-116) Medication Use Evaluation of Phytonadione at a Community Hospital in Northern Indiana

(3-117) Service evaluation into the use of inclisiran across North East London in a pharmacist led clinic at St Bartholomew’s Hospital (SBH)

(3-135) Evaluating the Impact of a Virtual Post-Acute Myocardial Infarction (AMI) Clinic in Lipid Management

(3-136) Safety and Efficacy of Full Intensive Phase Apixaban and Rivaroxaban following Extended Duration Parenteral Anticoagulation for the treatment of Acute Venous Thromboembolism

(3-146) Optimizing Anticoagulation Therapy in Saudi Arabia: The Evaluation of Pharmacist-Led Interventions on Physician Acceptance and Patient Care

(3-161) Evaluating Patient Eligibility of Switching from Warfarin to a Direct Oral Anticoagulant in an Anticoagulation Case Management Service

(3-162) Evaluation of Pharmacist versus Physician Led Inpatient Warfarin Management

(3-196) Utilization of Guideline-Directed Medical Therapy (GDMT) in HeartMate 3™ Patients: a single center cohort study

(3-217) The Evaluation of Four-Factor Prothrombin Complex Concentrates Utilization Following a Formulary Preference Change at the Largest Academic Medical Center in Louisiana

(3-228) Evaluating the Effectiveness and Safety of Direct Oral Anticoagulants (DOACs) Compared to Warfarin in Obese and Morbidly Obese Patients Taking Nonsteroidal Anti-inflammatory drugs (NSAIDs)

(3-229) Evaluation of Direct Acting Oral Anticoagulant Dosing and Duration in the Treatment of Venous Thromboembolism

(3-234) A retrospective evaluation on the use of ENTRESTO® (sacubitril/valsartan) for heart failure at an academic hospital

(3-235) Bridging the Gap: Addressing Racial Disparities in Treatment Outcomes for Second-Degree Heart Block

(3-248) Appropriate Indication of Long-Term Aspirin for Patients on Concurrent Warfarin Therapy at a Baltimore City Community Hospital Anticoagulation Clinic

(3-329) Clinical Outcomes of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants in Older Adults with Atrial Fibrillation

(3-354) Comparison of Time Spent in Internalized Normalized Ratio (INR) Goal Range Between Provider-Dosed and Pharmacist-Dosed Warfarin

(3-368) Patterns in Initial Dosing of Direct Oral Anticoagulants for Nonvalvular Atrial Fibrillation

(3-369) Assessment of Pharmacist Management of a Direct Oral Anticoagulant (DOAC) Dashboard

(3-376) Survival Benefit of Angiotensin Inhibitors in Black and White Patients with Heart Failure and Ejection Fraction <50%

(4-011) Impact of Ambulatory Clinical Pharmacy Services on Lipid Management in Patients with Atherosclerotic Cardiovascular Disease in an Outpatient Cardiology Clinic

(5-007) Navigating Antithrombin III Deficiency: Essential Insights for Patient Care

(5-063) Evaluation of Bromocriptine for the Treatment of Peripartum Cardiomyopathy

(5-107) Evaluation of readability of educational materials for coronary artery disease and the impact of health literacy and behavioral psychology on medication adherence and health outcomes.

(5-124) SGLT2 Inhibitors in Post-Myocardial Infarction to Prevent the Onset of Congestive Heart Failure Regardless of Diabetic Status

(5-135) Comparative Evaluation of Loading and Not Loading Clopidogrel in Patients with Minor Stroke or Transient Ischemic Attacks

(5-136) Evaluating the appropriate use of hydralazine in a community teaching hospital: A retrospective analysis

(5-137) Evaluation of Statin Intensity in Endovascular Abdominal Aortic Aneurysm Repair: A Retrospective Analysis

(5-148) Targeting Thrombosis: A Review of the Phase II and III Clinical Trial Findings for the Novel Factor XI and XIa Inhibitors

(5-157) Evaluation of Weight-Based Diltiazem Boluses on Critical Care Admissions for Patients with Atrial Fibrillation with Rapid Ventricular Response

(5-180) Evaluation of the Safety of Empagliflozin compared to Lisinopril Initiation in an In-patient Post-Cardiothoracic Surgery Patient Population

(5-187) Dofetilide-Induced Torsade de Pointes

(5-196) Environmental Scan of Anticoagulation-Related Oversight for Atrial Fibrillation in Five English-Speaking Countries

(5-197) Retrospective Evaluation of Provoked Left Ventricular Outflow Tract Gradient with Mavacamten Using Real-World Data from a Private Cardiology Practice Utilizing Pharmacist Monitoring

(5-248) Beating the Odds: Innovative Strategies for Preventing Cardiac Complications with LODOCO

(5-260) Accuracy of Indication Based Prescribing Documentation for Anticoagulants-A Retrospective Review

(5-307) Evaluation of Mineralocorticoid Receptor Antagonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure With Preserved Ejection Fraction

(5-316) Pharmacist-led Transitions of Care Program Impact on 30-day Heart Failure Readmission Rate

(5-324) Systematic Review: Efficacy and Safety of Intravenous Diltiazem vs. Metoprolol in Atrial Fibrillation with Rapid Ventricular Response (AFRVR)

(6-001) Evaluation of Sacubitril/Valsartan Initiation in Patients with Heart Failure

(6-020) Evaluation of Direct Oral Anticoagulant for Treatment of Acute Venous Thromboembolic Events in Patients with BMI Greater than 50kg/m2

(6-024) Venous Thromboembolism Agents in Patients with Nephrotic Syndrome

(6-026) Antithrombotic Therapy Prescribing Patterns after Percutaneous Coronary Intervention among Patients with Atrial Fibrillation on Anticoagulation

(6-051) Evaluation of Use of Renin-Angiotensin System Inhibitor Agents Post-Transcatheter Aortic Valve Replacement and Associated Heart Failure Outcomes

(6-064) Medication-use Evaluation of Continuous Infusion Intravenous Lidocaine at an Academic Medical Center

(6-096) Improving Transitions of Care: Tracking Pharmacist Interventions at Discharge to Promote Safe Use of Direct Acting Oral Anticoagulant

(6-117) Efficacy and Safety of Adjunctive Diuretics with Standard Diuretic Therapy in Acute Heart Failure: A Systematic Review and Meta-Analysis

(6-118) Heparin Infusion Reinitiation Best Practice Advisory Audit

(6-133) Evaluating the Utilization of Evidenced-based Sodium-Glucose Co-Transporter-2 Inhibitors in Patients Admitted for Heart Failure Exacerbation

(6-144) Evaluation of Intravenous vs. Oral Vitamin K in Patients with Supratherapeutic INR

(6-153) Direct-Acting Oral Anticoagulants in patients with Child Pugh Class C

(6-247) Characterization of Intravenous Ethacrynic Acid within an Academic Health-System: A Costly Delay in Challenging Sulfa Allergies?

(6-256) Effect of Ondansetron on corrected QT Prolongation in a Hospital Setting

(6-257) The Impact of Prochlorperazine and Trimethobenzamide on QTc Prolongation in a Hospital Setting

(6-271) Evaluation of Pharmacologic Blood Management Interventions in Adult Cardiac Surgery

(6-273) Optimizing Therapeutic Enoxaparin Dosing in Obese Patients: A Retrospective Review to Develop Strategies for Effective Anticoagulation

(6-282) Evaluation of GLP-1 Use in Cardiac Readmission Rates

(6-283) Impact of Pharmacist-Led Medication Reconciliation on Healthcare Utilization in Heart Failure: A Systematic Review and Meta-Analysis

(6-341) Evaluation of Gaps in Therapy for Lipid Management in Patients with Atherosclerotic Cardiovascular Disease in an Outpatient Cardiology Practice.

(6-342) Heparin-induced Thrombocytopenia (HIT) Management in Patients on Temporary Mechanical Circulatory Support (tMCS) Awaiting Heart Transplantation or Durable Left Ventricular Assist Device (LVAD) Implantation

(7-044) Loading Dose Reductions in Direct Oral Anticoagulants in Patients Who Received Prior Heparin Products for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

(7-055) Marijuana-Induced Vasospastic Angina

(7-061) Comparison of Twice Daily Versus Three Times Daily Unfractionated Heparin for DVT Prophylaxis in Critically Ill Population

(7-062) The Effect of Nicotine and its Major Metabolite, Cotinine, on Platelet Aggregation, Secretion, and Thrombus Formation

(7-066) Safety and Efficacy of Diltiazem for the Treatment of Atrial Fibrillation with Rapid Ventricular Response in Obese Patients

(7-068) Assessing Prescribing Practices for Initial Parenteral Anticoagulant Selection in the Emergency Department: A Retrospective Evaluation of Unfractionated Heparin and Low Molecular Weight Heparin.

(7-084) Comparison of Twice Daily Versus Three Times Daily Unfractionated Heparin for DVT Prophylaxis in General Medicine Population

(7-085) Comparison of Twice Daily Versus Three Times Daily Unfractionated Heparin for DVT Prophylaxis in Surgical Patient Population

(7-086) Evaluation of enoxaparin venous thromboembolism prophylaxis dosing compliance in overweight and obese patients at a community hospital

(7-099) Support of transitions of care pharmacists in discharge rounds for acute stroke inpatients

(7-140) Decoding Heart Health: A Comprehensive Review of Cardiovascular Drugs Through Pharmacogenetic Lenses

(7-149) Evaluation of Antithrombotic Therapy at Discharge in Chronic Atrial Fibrillation Patients Post Coronary Artery Bypass Surgery With Left Atrial Appendage Occlusion

(7-150) Outpatient inclisiran administration: a pragmatic, multi-center evaluation

(7-151) Salt-sensitive Hypertension and the Microbiome: A Scoping Review

(7-152) Systematic Review of the Impact of Sacubitril/Valsartan Treatment on Depression and Anxiety in Patients with Heart Failure

(7-180) Evaluation of anticoagulation strategies in HeartMate 3 LVAD patients at a Tertiary, Academic Medical Center

(7-192) Cross-Sectional Study of National P2Y12 Inhibitor Prescribing in the United States Between 2009 and 2019

(7-204) Stroke Management in a Geriatric Patient with Lambl Excrescences

(7-211) Real-World Evaluation of DOAC Anti-Xa Monitoring

(7-239) Implementation of a Pharmacy Monitoring Service for Warfarin Therapy Management in an Acute Care Rehabilitation Hospital

(7-240) The impact of somatostatin use in post-CABG adults with chylothorax on chest tube output or time to chest tube removal

(7-258) Assessing Correlations Between Immunologic Positive and Functional Assay Negative Heparin-Induced Thrombocytopenia Cases in Community Hospital

(7-287) Long-Term Intravenous Iron Therapy for Outpatients with Heart Failure and Iron Deficiency

(7-296) Evaluating Dofetilide and Sotalol Use in Arrhythmias Across a Health System

(7-297) Evaluating the Use of Guideline-Directed Medical Therapy for Heart Failure in Urban and Rural Areas

(7-327) Impact of a Pharmacist Telehealth Intervention on Medication Prescribing and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction

(8-009) Impact of Automating an Anticoagulation Dashboard

(8-010) Decreasing Unfractionated Heparin Use in Patients Eligible for Alternatives in the Emergency Department

(9-023) Comparison of Treatment and Outcomes of Acute Hypertension in Hospitalized Patients in a Community Hospital

(9-025) Assessment of a Heparin Infusion Protocol in Obese Patients in a Community Hospital

(9-051) Evaluation of Efficacy of Fixed-Dose 4-Factor Prothrombin Complex Concentrate (4F-PCC) vs Weight-Based Dose 4F-PCC in Patients With Major Bleeds on Factor-Xa Inhibitors

(9-055) Anticoagulation Prescribing Trends in Patients with Factor V Leiden: A Retrospective Analysis

(9-065) Retrospective Analysis of Outcomes After Bioprosthetic Valve Replacement With or Without Anticoagulation

(9-068) Retrospective Review of Guideline Directed Medical Therapy (GDMT) Medications and Occurrence of Heart Failure Readmission

(9-084) Retrospective Chart Review Comparing Pharmacist versus Physician Dosing of Warfarin in Hospitalized Patients

(9-112) Impact of 4-Factor Prothrombin Complex Concentrate (4F-PCC) Protocol in Patients Not on Anticoagulants

(9-129) Impact of Fixed-Dose Prothrombin Complex Concentrate (Human) versus Weight-Based Dosing in the Emergent Anticoagulation Reversal of Warfarin

(9-148) Management of Heparin IV Infusion for Patients with Oral Factor Xa Inhibitors (OFXai) Interference

(9-164) Impact of Pharmacist-facilitated Interventions on Heart Failure Patients’ Medication Therapies and Clinical Outcomes

(9-186) Impact of Pharmacy Transitions of Care on Heart Failure GDMT Optimization

(9-225) Optimizing Time to Therapeutic INR with Warfarin through a Pharmacy to Dose Consult Program: A Retrospective Review

(9-250) Evaluation of an embedded 4T scoring clinical decision tool on the assessment and treatment of heparin induced thrombocytopenia (HIT)

(9-251) Impact of Pharmacist Intervention on Direct Oral Anticoagulant (DOAC) Affordability for Adult Anticoagulation Clinic Patients

(9-258) Evaluation of Direct Oral Anticoagulation Reversal Agent Utilization at Nuvance Health

(9-263) Evaluation of Heparin-Induced Thrombocytopenia Testing to Improve Anticoagulation Stewardship in an Acute Care Setting

(9-264) Safety and efficacy of warfarin versus direct oral anticoagulants for management of post-coronary artery bypass grafting atrial fibrillation

(9-272) Assessing the Frequency and Effects of Inappropriate Direct Oral Anticoagulant Prescribing in Outpatient Discharge

(9-275) Gap Analysis Evaluating Direct Oral Anticoagulant Monitoring in a Community Hospital Compared to Anticoagulation Forum Standards

(9-307) Correlation of 4T score, m4T, and LLL with Positive Heparin Antibodies and Serotonin Release Assays (SRAs) in Cardiac Surgery ICU Patients

(9-308) Evaluation of Protamine Dosing Strategies Following Cardiopulmonary Bypass

(9-309) Evaluation of Safety and Efficacy of Venous Thromboembolism Prophylaxis with Unfractionated Heparin versus Enoxaparin in Obese Patients

(9-310) Guideline Directed Medical Therapy Prescribing and Safety in Patients with Acute Decompensated Heart Failure

(9-321) The Impact of Pharmacist Discharge Education in Preventing Acute Heart Failure Rehospitalizations

(9-324) Assessment of the Safety and Efficacy of Therapeutic Enoxaparin vs. Unfractionated Heparin in the Renally Insufficient

(9-343) Evaluation of cangrelor prescribing trends across an acute care health-system

(9-344) Evaluation of Direct Oral Anticoagulants in Comparison to Vitamin K Antagonists in the Management of Left Ventricular Thrombus

(9-353) Impact of iron administration in iron deficient patients with heart failure with reduced ejection fraction.

(9-359) Acetazolamide versus Metolazone in Acute Heart Failure

(9-400) Gadopiclenol Use in Cardiovascular Morphology and Function in Magnetic Resonance Imaging

(9-407) Evaluating the Impact of Pharmacist Led Heparin Infusion Monitoring

(9-427) Comparing Bleeding Events in Underweight Patients Receiving Standard Versus Reduced Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis

(9-432) Evaluation of Initial Diuretic Dosing in Diuretic-Naive Patients with Acute Heart Failure

(9-435) Evaluation of Bivalirudin Titration Protocol in Patients With Temporary Heart Pumps

(9-440) Evaluation of Outcomes Associated with Parenteral Anticoagulation Followed by Full Initial Dosing of Apixaban or Rivaroxaban in Newly Acute VTE Patients

(9-448) Comparison of Peak Anti-Xa Levels After the Second and Third Administrations of Enoxaparin

(9-467) Comparing Prophylactic Amiodarone Versus No Amiodarone for the Prevention of Postoperative Atrial Arrhythmias in Cardiothoracic Surgery Patients

(9-470) Evaluating the Efficacy and Safety of Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients

(9-476) Comparison of Furosemide and Metolazone Based Regimens to Furosemide Drip in Acute Heart Failure

(9-477) Effect of Abdominal Wall Thickness on Anti-Xa Levels During Enoxaparin Prophylaxis in Obese Trauma Patients

(10-030) Evaluation of Direct Oral Anticoagulant Utilization for Venous Thromboembolism Treatment in Obese Spinal Cord Injury Rehabilitation Patients

(10-033) Evaluating the Efficacy of a Standardized Diuretic Order Panel versus Provider-Prescribed Diuretic Dosing in Acute Decompensated Heart Failure

(10-034) Impact of Dapagliflozin Versus Empagliflozin on Renal Function and Diuretic Response in Patients with Acute Decompensated Heart Failure at a Tertiary Care Community Teaching Hospital.

(10-037) Pharmacist Management and Monitoring of Rivaroxaban at a Community Teaching Hospital

(10-045) Developing an Interprofessional Workflow to Address The Needs of Native Hawaiian Patients with Methamphetamine Associated Cardiomyopathy

(10-062) Efficacy and Safety of Sacubitril-Valsartan in Patients with Heart Failure: A Post-ACEi/ARB Switch Study

(10-063) Evaluation of Higher Dose Enoxaparin for Venous Thromboembolism Prophylaxis in Patients with a Body Mass Index > 40

(10-076) Impact of Initial Parenteral Anticoagulation on Direct Oral Anticoagulant Loading Dose for Acute Venous Thromboembolism: Multicenter Study

(10-083) Impact of Initial Parenteral Anticoagulation on Direct Oral Anticoagulant Loading Dose for Acute Venous Thromboembolism: Multicenter Study

(10-084) Intravenous Metoprolol for Management of Atrial Fibrillation with Rapid Ventricular Response in the Emergency Department: A Medication Use Evaluation

(10-121) Impact of Reflex Serotonin Release Assay (SRA) on Heparin Induced thrombocytopenia (HIT)

(10-136) Evaluation of Appropriate Intravenous Push Antihypertensive Medication Use for the Treatment of Inpatient Asymptomatic Hypertension at an Urban Safety-Net Hospital

(10-143) Retrospective Review of Sodium-Glucose Cotransporter-2 inhibitors in Patients with Heart Failure on Discharge

(10-145) Evaluation of the Safety and Efficacy of Subcutaneous Heparin Prophylaxis in Patients Undergoing Continuous Renal Replacement (CRRT)

(10-154) Evaluation of Time to Reach Therapeutic Anticoagulation with Heparin Infusions in a Single Community Hospital

(10-160) Evaluation of Euglycemic Diabetic Ketoacidosis in Patients Using Sodium-glucose cotransporter-2 inhibitors

(10-161) Evaluation of Left Ventricular Ejection Fraction Improvement and Guideline Directed Medical Therapy Prescribing Trends in Patients with Newly Reduced Ejection Fraction

(10-182) Evaluating the impact of pharmacist intervention and protocol adherence for initiation of sotalol and dofetilide for atrial fibrillation in an inpatient setting.

(10-189) Impact of Direct Oral Anticoagulant (DOAC) Management Following Implementation of Pharmacist-Directed Monitoring Service

(10-218) Anticoagulation Strategies after Left Ventricular Thrombus

(10-219) Dofetilide Initiation in a Tertiary Medical Center: A Medication Use Evaluation

(10-235) Evaluating Guideline-Directed Medical Therapy Compliance and Its Effect on Readmission Rates in Patients with Heart Failure with Reduced Ejection Fraction

(10-237) Venous Thromboembolism (VTE) prophylaxis in Post knee and hip replacement: link the practice to the evidence at Sheikh Khalifa Medical City

(10-282) Incidence of ketoacidosis with sodium-glucose co-transporter-2 inhibitors in patients with Type 2 Diabetes, and or Heart Failure.

(10-283) Intravenous Diltiazem Used for Atrial Fibrillation and Association with Heart Failure Outcomes

(10-287) Prophylactic Amiodarone vs. Early Discontinuation After Coronary Artery Bypass Grafting and/or Valve Surgery via Sternotomy for Prevention of Postoperative Atrial Fibrillation

(10-294) Recurrent Venous Thromboembolism in Patients With Abbreviated Versus Full Lead-in Dosing of Apixaban or Rivaroxaban​

(10-300) To Impel Anticoagulation with Impella or Not

(10-308) Evaluating Diuretic Optimization in Hospitalized Patients with Heart Failure Using Remote Dielectric Sensing (ReDS) Vest Analytics

(10-335) Pharmacist Impact on Optimization of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure: A Retrospective Cohort Study

(10-357) Determining the Therapeutic Dosage of Enoxaparin Anticoagulation Among Morbidly Obese Patients After Implementation of an Automatic Clinical Pharmacy Anti-Xa Monitoring Service Using Enoxaparin Dosing Protocol

(10-362) Andexanet Alfa and Four-Factor Prothrombin Complex Concentrate (4F-PCC) for the Reversal of Rivaroxaban and Apixaban-Associated Intracranial Hemorrhages

(10-371) Reaching Therapeutic – A Comparison of Dosing Heparin

(10-382) Analysis of Appropriate Heparin Administration for Acute Coronary Syndrome using High-Sensitivity Troponin Levels

(10-384) Evaluating the Use of Empagliflozin in Acute Heart Failure Patients at a Community Hospital

(10-401) Efficacy of 4-Factor Prothrombin Complex Concentrate in Managing Direct Oral Anticoagulant-Related Intracranial Hemorrhages: A Comparative Study with ANEXXA-I Trial Outcomes

(10-409) Evaluating the Time to Therapeutic Level of Anti-Factor Xa versus Activated Thromboplastin Time Monitoring for Heparin Continuous Infusions

(10-441) Impact of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on Readmission Rates in Older Adults with Chronic Heart Failure: A Retrospective Chart Review.

(10-447) Assessing Dosing of Direct Oral Anticoagulants Initiated in the Emergency Department at a Community Hospital

(10-450) Evaluation of Adherence to IV Iron with Pharmacy-Led IV Iron Protocol in Patients with Heart Failure

(10-455) Impact of a Pharmacist-Led Warfarin Management Protocol Compared to Provider-Led Management in an Academic Community Hospital

(10-466) Impact of Pharmacist-Led Anticoagulation Management Service of Patients on DOACs in an Outpatient Setting.

(11-005) Evaluation of Time to Recurrent VTE: A Multicenter Study Comparing Standard vs. Reduced Lead-in Durations in Patients Initially Receiving Parenteral Anticoagulation

(11-019) Evaluation of Therapeutic Enoxaparin Dosing in Patients with Severe Renal Impairment

(11-036) LV-Advantage of Guideline-Directed Medical Therapy (GDMT) in Left Ventricular Assist Device (LVAD) Patients

(11-042) Time to Therapeutic aPTT for a Nursing Driven Heparin Protocol

(11-050) Assessing the Administration of Full Versus Half Loading Dose to Transition Between P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

(11-059) Evaluation of Current Outpatient DOAC Management Practices Within Trinity Health Grand Rapids

(11-064) Anti-Xa Level Monitoring in Trauma Patients on Enoxaparin for Venous Thromboembolism Prophylaxis

(11-065) Evaluation of Argatroban Dosing and Time to Therapeutic aPTT

(11-075) Evaluation of DOAC use for anticoagulation in patients with Atrial Fibrillation and Class III Obesity

(11-098) Evaluation of Prescribing Practices of Lipid-Lowering Therapies and Optimization

(11-119) Comparison of Enoxaparin and Unfractionated Heparin for Venous Thromboprophylaxis in Renally Impaired Patients

(11-138) Impact of Integrating a Pharmacist in a Heart Failure Clinic on Readmission Rates

(11-147) Evaluation of Pharmacist Driven Anti-Xa Protocol in Hospitalized Patients

(11-149) Evaluation of Traditional Lead-in Versus Adjusted Lead-in Dosing of Apixaban for the Treatment of Venous Thromboembolism

(11-155) Bleeding Complications Among Patients with Coronary Artery Disease on Extended Dual Antiplatelet Therapy

(11-174) Evaluating the Appropriateness of Vitamin K Use for Warfarin Reversal in a Safety Net Hospital

(11-179) Comparative analysis of risk prediction between the PREVENT Calculator and Atherosclerotic Cardiovascular Disease Risk Estimator in Federally Qualified Health Center patients.

(11-195) Optimizing Cardiac Care: Implementing an Outpatient Cardiologist Pharmacist to Enhance Patient Outcomes and Medication Management for Heart Failure Patients

(11-198) Evaluation of a Pharmacist-Managed Intravenous to Subcutaneous Insulin Protocol in Postoperative Cardiac Surgery Patients

(11-213) Evaluation of Balfaxar® for anticoagulation reversal in a community hospital

(11-230) Evaluation of Institution-Specific Low Intensity Unfractionated Heparin Protocol

(11-251) Provider versus Protocolized Anticoagulation for Impella Devices

(11-278) How Long to Hit the Mark: Achieving Therapeutic aPTT with Heparin

(11-282) Assessing the Safety and Efficacy of Weight-Based Intravenous Heparin Protocols within a Multi-Hospital Health System in New Jersey

(11-290) Impact of Anticoagulation Therapy in Infective Endocarditis

(11-299) Safety of Initiating Sodium-glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients with a History of Urinary Tract Infections (UTIs)

(11-325) Assessment of Institutional Time to Therapeutic Range (TTR) in Patients Receiving Warfarin at an Academic Medical Center

(11-330) Optimization of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction Following Admission for Acute Decompensated Heart Failure on Non-Cardiovascular Services

(11-333) Cost-effective study comparing fixed versus weight-based dosing of 4-factor Prothrombin Complex Concentrate (4F-PCC) in patients with major bleeding associated with oral factor Xa (FXa) inhibitors

(11-335) BITE: Bleeding Incidence related to VTE Thromboprophylaxis in Medical and Surgical Patients - an Evaluation

(11-348) Evaluation of Enoxaparin Dosing and Increasing Bleeding Risks in MICU and General Medicine Patients

(11-353) Evaluating appropriateness of therapy for heart failure patients at a tertiary academic medical center and assessing clinical impact of pharmacist-led patient education on readmission rates

(11-363) Evaluation of intravenous metoprolol vs. diltiazem for rate control of atrial fibrillation in heart failure with preserved ejection fraction.

(11-364) Potential Impact of BMI on Bleed Rates in Patients Taking Rivaroxaban or Apixaban

(11-379) Evaluating the Efficacy of Inclisiran in Patients with Hypercholesterolemia in an Ambulatory Care Setting

(11-387) Outcomes in Hospitalized Venous Thromboembolism Patients Receiving Full Versus Abbreviated Loading Durations of Direct Oral Anticoagulant Therapy Subsequent to Parenteral Anticoagulation

(11-392) Efficacy and Safety of Rivaroxaban Compared to Enoxaparin for Venous Thromboembolism Prophylaxis in Medically Ill Hospitalized Patients

(11-393) Intravenous (IV) Diltiazem Versus Metoprolol for Treatment of Atrial Fibrillation with Rapid Ventricular Response

(11-402) Antithrombotic Stewardship: Evaluating Periprocedural Antithrombotic Management for Lumbar Punctures at a Large Academic Medical Center

(11-404) Managing Anticoagulation Transitions: The Role of Apixaban

(11-414) Comparative Efficacy and Safety of Apixaban versus Enoxaparin for Venous Thromboembolism Prophylaxis in Bariatric Surgery Patients.

(11-422) Evaluation of the Impact of a Meds to Beds Program on Clinical Outcomes for Patients Undergoing Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction

(11-437) Evaluation of Efficacy and Safety of Heparin Infusion Dosing in Obese Patients Compared with Non-Obese Patients

(11-444) Evaluation of guideline-directed medical therapy & target dose prescribing practice in discharged heart failure with reduced ejection fraction patients in an acute care teaching hospital.

(11-446) Potential Risk of Ganoderma lucidum (Reishi Mushrooms) in Patients on Warfarin

(11-466) Evaluating the Impact of Clinical Pharmacy Services on Time in Therapeutic Range in Long- Term Warfarin Patients: A Retrospective Cohort Study

(12-008) Evaluation of Enoxaparin Doses in Patients Requiring Neuraxial Anesthesia and Deep Peripheral Nerve Blocks

(12-011) Prevalence of Gastrointestinal Bleeding in Inpatients Receiving Oral Anticoagulation with or without Concomitant Antiplatelet Therapy

(12-019) Impact of Pharmacist Discharge Review of Oral Anticoagulation Medications in Hospitalized Patients

(12-036) Evaluation of Midodrine Use in Patients with a Left Ventricular Ejection Fraction Less than 40%

(12-044) Real World Use of Mavacamten for hypertrophic obstructive cardiomyopathy for patients in Western North Carolina

(12-047) Comparison of Bivalirudin Versus Heparin in Patients Receiving Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

(12-048) Deficits in Warfarin Discharge Planning: Improving Transitions of Care for Patients on Warfarin at a Community Teaching Hospital

(12-060) Evaluation of Direct Oral Anticoagulants Dosing for Patients with Atrial-Fibrillation Post-Orthopedic Surgery

(12-061) Time to Beta Blocker Initiation and Post-Operative Atrial Fibrillation Rates in Cardiac Surgery Patients: Can We Do Beta?

(12-078) Evaluation of initial loop diuretic dosing in patients admitted for acute decompensated heart failure with acute volume overload

(12-096) Evaluation of Venous Thromboembolism (VTE) Prophylaxis Choice and Duration Prescribed at Discharge for Orthopedic Patients

(12-103) Determinants of Antiarrhythmic Agent Selection in Patients with Atrial Fibrillation and Heart Failure

(12-104) Initiation of sodium glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction prior to discharge and hospital readmission rates

(12-105) Iron Study Availability in Patients Admitted With Acute Decompensated Heart Failure

(12-112) Retrospective Multi-Site Cohort Study Describing Concordance with Institutional Guidelines in Patients Who Received Vitamin K for Warfarin Reversal

(12-113) Retrospective, Multicenter Evaluation of the Number of Guideline-Directed Medical Therapies and All-Cause Readmission in Patients Discharged after a Heart Failure Exacerbation

(12-134) Pharmacist-led interventions in antiarrhythmic therapy: Results from a new clinic initiative

(12-154) Safety of Rivaroxaban and Apixaban in Acute Kidney Injury

(12-178) Evaluation of an Off-Label Dose Reduction of Apixaban in Patients Eighty Years and Older Living with Atrial Fibrillation

(12-179) Outcomes Associated with QTc Monitoring in Patients Receiving Oral Oncolytic Therapy

(12-184) Assessing Rates of Inappropriate Aspirin Use and the Impact of a Pharmacy Led Deprescribing Initiative

(12-187) Evaluation of the Impact of Timing of Post-Operative Beta-Blocker Initiation in Cardiothoracic Surgery Patients

(12-188) Comparative Diuretic Efficacy of Intravenous Versus Oral Acetazolamide with Loop Diuretic Administration

(12-212) Discharge Therapy and Readmission Rates in Patients Hospitalized with an Acute Exacerbation of Heart Failure with Reduced Ejection Fraction

(12-268) Assessing Indications for Concomitant Use of Aspirin and Warfarin in Patients in an Anticoagulation Clinic

(12-269) Evaluation of guideline recommended therapy for stroke and systemic embolism prevention in non-valvular atrial fibrillation patients within the Allegheny Health Network Anticoagulation Clinic

(12-270) Evaluation of the Utilization of Catheter Directed Thrombolysis with Alteplase

(12-289) Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Utilization and Prescribing in Patients with Concomitant Type 2 Diabetes Mellitus and Heart Failure

(12-320) Evaluating the safe use of class III antiarrhythmic therapy in the hospital setting

(12-328) Assessment of Guideline-Directed Medical Therapy Utilization Prior to Hospitalization in Patients with Acute Decompensated Heart Failure

(12-329) Evaluating Antithrombotic Therapy for Hospitalized and Emergency Department Patients with Non-valvular Atrial Fibrillation (NVAF)

(12-337) Evaluation of Amiodarone Monitoring in the Outpatient Setting

(12-340) Pharmacy driven provider education about optimal guideline directed medical therapy dosing to improve therapeutic dosing practices in heart failure patients with reduced ejection fraction

(12-346) Effect of Anti-Xa Level Monitoring on Enoxaparin Dosing in Obese Patients

(12-347) Evaluation of Implementation of an Intended Plan for Triple Therapy at Discharge in Patients with an Indication for Anticoagulation Post-Percutaneous Coronary Intervention

(12-381) Evaluation of Cangrelor Use in a Community Health System

(12-382) Intravenous Chlorothiazide Use in a Community Health System

(12-384) Evaluation of Anticoagulation Prescribing Practices for Non-Valvular Atrial Fibrillation for Patients With a History of Bariatric Surgery

(12-393) Evaluating prescribing trends of guideline-directed heart failure therapy before and after pharmacist-led education

(12-399) Assessing the Utility of Enoxaparin Anti-Xa Monitoring in Obesity for Venous Thromboembolism (VTE) Prophylaxis on Clinical Outcomes in the Hospital Setting

(12-402) Impact of Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) on Renal Function in Left Ventricular Assist Device (LVAD) Population

(12-420) Anti-Xa monitoring in adult trauma patients weighing over 100 kilograms

(12-425) Colchicine Use in Cardiovascular Disease Prevention

(12-429) Impact of Pharmacist Monitoring of Anticoagulants on Venous Thromboembolism Prophylaxis Refusal Rates

(12-444) Calcium Administration in Massive Transfusion Protocol

(13-002) Comparing the Safety and Efficacy of Direct Oral Anticoagulants to Warfarin for Venous Thromboembolism Treatment in Obese Patients

(13-013) Rivaroxaban vs Enoxaparin in post-operative bariatric patients for thromboprophylaxis

(13-022) Impact of Expanded Dosing in Unfractionated Heparin on Efficacy and Safety During Treatment of Acute Coronary Syndrome and Venous Thromboembolism at a Community Hospital

(13-037) Assessing Heparin Administration in the Hospital: A Comparative Review of One-Time Dosing Versus As-Directed Dosing Protocols.

(13-056) Evaluating the Effect of Adding Dapagliflozin to Formulary on 30-Day Readmission Rates in Heart Failure Patients

(13-060) Evaluation of Anticoagulation Failures in a Community Hospital

(13-089) Apixaban Safety and Efficacy for the Treatment of Venous Thromboembolism in Patients on Dialysis

(13-090) Blood Glucose Control in Post-Coronary Artery Bypass Graft Patients

(13-091) Rates of Gastrointestinal Bleeds in Patients Taking Concomitant Dual Antiplatelet Therapy and SSRI/SNRI Therapy Within One Year of Acute Coronary Syndrome

(13-092) Safety evaluation of apixaban indicated for venous thromboembolism in patients with acute kidney injury

(13-103) Evaluating Heparin Drips in Inpatient Care: Efficacy, Safety, and Anticoagulation Management

(13-109) Impact of Loading Doses of Direct Oral Anticoagulants on Left Ventricular and Left Atrial Thrombus

(13-123) Evaluating the Efficacy and Safety of a Reduced Lead-In Duration of DOACs for VTE treatment

(13-124) Evaluating the Recurrence of Venous Thromboembolism and Bleeding Incidence with Apixaban in Patients with Colon Cancer

(13-151) Evaluation of Major Bleeding Risks in Patients with Diltiazem or Metoprolol on Concomitant Apixaban at CHRISTUS Spohn Shoreline Hospital

(13-176) Evaluation of Outcomes with Adjunct Diuretic Therapy in Acute Decompensated Heart Failure

(13-187) Ticagrelor vs. clopidogrel post-PCI and re-admittance with bacterial pneumonia

(13-199) Impact of an Additional Therapy (2 vs. 3) Guideline-Directed Medical Therapy on 30-Day Readmissions for Heart Failure with Reduced Ejection Fraction: A Retrospective Chart Review

(13-220) Pre-Post Analysis of Implementing a Resident-Driven Anticoagulation Stewardship Program

(13-223) Evaluating Prescribing Patterns and Clinical Outcomes of The Use of Intravenous Iron in Patients with Acute Heart Failure

(13-242) Evaluation of Outcomes in Obese vs. Non-Obese Patients on a Heparin Drip in Venous Thromboembolism

(13-268) Evaluation of Anticoagulation Management for the Treatment of Acute Heparin-induced Thrombocytopenia in a Community Health System

(13-274) Evaluation of Contributing Factors in 90-Day Heart Failure Readmissions and Pharmacy-Led Optimization Opportunities

(13-276) Comparative Analysis of Clinical Outcomes in Unfractionated Heparin Dosing Protocols; Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring

(13-285) Implementation of a Warfarin Patient Self-Management (PSM) Program in Patients on Chronic Warfarin Therapy

(13-291) Enoxaparin for Venous Thromboembolism (VTE) Prophylaxis in Patients with a Body Mass Index (BMI) less than 18.5 kg/m2 and greater than 35 kg/m2

(13-313) Development of Pharmacist Standardized Workflow to Improve Prescribing Patterns of Post-Myocardial Infarction Goal Directed Discharge Medications

(13-316) Implementation of a Warfarin to Direct Oral Anticoagulant Switch Protocol at a Community Hospital

(13-317) Optimizing and Implementing a Standard Heparin Infusion Protocol Across a Community Based Health System

(13-319) Transitioning from Nursing-Driven aPTT Heparin Monitoring to Pharmacist-Driven Anti-Xa Heparin Monitoring

(13-343) Analysis of heart failure, acute myocardial infarction, and coronary artery bypass graft readmissions at Providence St. Peter Hospital and Providence Centralia Hospital.

(13-344) Retrospective Analysis of 30-Day Readmission in Patients with Congestive Heart Failure

(13-350) Impact of Discordant aPTT and Bivalirudin Levels on Bleeding and Clotting Outcomes in Critically Ill Pediatric Patients Receiving VA-ECMO: A Single-Center, Retrospective Cohort Study

(13-363) Rate vs rhythm control for new-onset atrial fibrillation management in heart failure with preserved ejection fraction, a retrospective cohort study

(13-377) Thrombosis risk with heparin versus sodium bicarbonate Impella purge solutions